From: dana-farber.org A new study from Dana-Farber Cancer Institute shows that cases of stage IV breast cancer, a common but largely difficult to treat disease, are increasing both in incidence and as a proportion of all breast cancer diagnoses. According to the findings, published today JAMA Network Open, the incidence rate of stage IV breast cancer has increased significantly, from …
Why Black Women Are Less Likely to Survive a Breast Cancer Diagnosis
From: healtthline.com Key takaways Black women have a 5-year breast cancer survival rate of 84% compared to 93% for white women, making breast cancer the leading cause of cancer-related deaths for Black women. These disparities stem from systemic racism affecting income, insurance, and healthcare access — not biological differences. Racism is increasingly recognized as a root cause of less favorable …
Understanding Female Breast Cancer Before Age 40
From: healthline.com According to the National Cancer Insititute, the average 30-year-old American woman has a 1 in 204Trusted Source chance of receiving a breast cancer diagnosis within the next 10 years. By age 40, this risk increases to 1 in 65, and by age 70, this risk is 1 in 24. Although the odds of female breast cancer are much …
Yale-led technology receives FDA approval for breast cancer treatment
By: Meg Dalton From: yale.edu More than a decade ago, Yale chemist Craig Crews founded a biotechnology company in New Haven based on his pioneering research into PROTACs (or PROteolysis TArgeting Chimera), a technology that treats certain types of cancer and other diseases by degrading the proteins that cause them. That company, Arvinas, has since developed a PROTAC therapy called vepdegestrant, …
Breaking Down the Treatment Options for HER2-Negative Breast Cancer
From: healthline.com Treatment options for HER2-negative breast cancer include surgery, hormone therapy, radiation therapy, targeted therapy, chemotherapy, and immunotherapy. Treatment for HER2-negative breast cancer will depend on factors such as hormone receptor status, cancer stage, and your age and overall health. The goal of treatment for HER2-negative breast cancer can vary based on the extent of your cancer. It may …
Flap vs. Implant Reconstruction: What New Research Says
From: breastadvocateapp.com Breast reconstruction is a deeply personal decision. There is no one “right” choice. Only what’s right for you. A new 2025–2026 study compares two of the most common options: Flap reconstruction (using your own tissue) Implant-based reconstruction Let’s break it down in simple terms. What is flap reconstruction? Flap reconstruction uses tissue from your own body. Usually from …
Low-dose drug cuts breast density (treatment) up to 26% with fewer side effects
By: Karolinska Institutet From: medicalxpress.com Low doses of the investigational medicinal product endoxifen reduce breast density to the same extent as the standard treatment tamoxifen, but without causing such troublesome side effects. This is shown by a new study from Karolinska Institutet published in the Journal of the National Cancer Institute. The results may have implications for future preventive treatment …
Intermediate PRRX1 Levels Drive Breast Cancer Metastasis Risk
By: Pooja Toshniwal Paharia From: azolifesciences.com Breast cancer’s most high-risk cells may be determined at the tumor’s origin, where a fine-tuned balance between invasion and growth dictates whether cancer spreads or remains dormant. A recent study published in Nature Communications suggests that the metastatic potential of breast cancer cells may be established far earlier than previously recognized, within the original tumor …
FDA Approves Vepdegestrant for ER+/HER2– Advanced Breast Cancer With an ESR1 Mutation
By: Chris Ryan From: onclive.com The FDA has approved vepdegestrant (Veppanu) for the treatment of adult patients with estrogen receptor (ER)–positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least 1 line of endocrine therapy.1,2 The approval was backed by data from the phase 3 VERITAC-2 trial (NCT05654623), which demonstrated …
Datopotamab Deruxtecan Improves Survival Outcomes in Advanced Triple-Negative Breast Cancer
By: Quincy Attobrah From: oncnursingnews.com Datopotamab deruxtecan (Datroway) demonstrated improved progression-free survival (PFS) and overall survival (OS) compared with standard chemotherapy in patients with previously untreated, advanced triple-negative breast cancer (TNBC) who were not eligible for immunotherapy, according to results from the phase 3 TROPION-Breast02 trial. The findings, published in Annals of Oncology, address a significant unmet need in TNBC, …